Physiologic Measure of VIPN (NCT04786977)
Development of a Physiologic Measure of Vincristine Induced Peripheral Neuropathy in Children and Adolescents
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is the development of a physiologic endpoint using a novel technology that would provide an objective, easy to use and more sensitive assessment of VIPN in children and adolescents. The ability to more easily detect and monitor VIPN, even before it is clinically evident, would facilitate optimizing the dosing of vincristine for maximal disease response while minimizing the risk of lifelong functional deficits affecting quality of life. This approach would also enable the development of specific therapies to minimize or eliminate the occurrence of VIPN in children and adolescents. This is a single site study that aims to develop a novel device to evaluate and characterize vincristine-induced neuropathic pain. The investigators will enroll patients with ALL following the Delayed Intensification (DI) phase of treatment. At each study visit, the investigators will evaluate the nPRD as well as the TNS-PV. The nPRD will inform the neuropathy index which will be used to compare to the TNS-PV. We anticipate a correlation between the two.
Who can join: Review the eligibility criteria below.
Location: Children's National Health System — Washington D.C., District of Columbia
Age range: 6 Years to 18 Years
🧪 Interventions in This Study
- No Intervention, Observational Study (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Children's National Health System — Washington D.C., District of Columbia
📞 Contact the Study Coordinator
Phone: (202) 476-4867
Email: jfinkel@cnmc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chemotherapy-induced Peripheral Neuropathy
- The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) — Boston, Massachusetts
- NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy — Iowa City, Iowa
- Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) — Toronto, Ontario
- Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) — Clermont, Florida
- Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy — Houston, Texas
- PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy — Middletown, Connecticut
Explore by condition: All Chemotherapy-induced Peripheral Neuropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.